Abstract:Combination therapy via stimulus-responsive drug release is known to improve treatment efficacy and minimize side effects. However, the use of low-abundance cancer biomarkers as molecular triggers to induce efficient drug release for combination therapy still remains a challenge. Herein, we developed a dual microRNA-responsive drug nanocarrier for catalytic release of doxorubicin (Dox) and small interfering RNA (siRNA) in cancerous cells for combined chemotherapy and gene therapy with logic operation. The nanocarrier is constructed by assembling two duplexes of DNA/RNA and Dox molecules onto DNA-functionalized gold nanoparticles. Two microRNA molecules (miRNA-21 and miRNA-10b overexpressed in MDA-MB-231) could alternatively catalyze the disassembly of the nanocarrier through a thermodynamically driven entropy gain process, during which Dox molecules are released, and the two pairs of released DNA/RNA duplex hybridize to generate siRNA (siBcl-2) in situ by strand displacement reactions. Quantum dots are used to track the process in living cells. The AND logic gate-based drug release system allows effective treatment of specific cancer cell types according to miRNA expression patterns. This strategy represents an effective means to overcome multidrug resistance and improve therapeutic effects.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acsami.0c09494?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acsami.0c09494</a>.Materials and methods including characterization of GNPs (Figure S1), characterization of DNA2-QD (Figure S2), characterization of DNA hybridization (Figure S3), PAGE analysis of the strand displacement reaction (Figure S4), FL and ICP data for determination of the D1D′1C and D2DQ number (Figure S5), characterization of catalytic disassembly of Dox-GNC (Figure S6), stability test of Dox-GNC (Figure S7), agarose gel electrophoresis characterization of disassembly of GNC (Figure S8), determination of Dox loading on GNC (Figure S9), specificity of Dox-GNC triggered by dual miRNAs for drug release (Figure S10), stability of GNC at physiological circumstances (Figure S11), cell viabilities of three cell lines treated with GRR-Dox in the presence or absence of fuel DNA for different times (Figure S12), cell viabilities of MDA-MB-231 cells transfected with waste DNA (Figure S13), cell viabilities of MDA-MB-231 cells under different treatments (Figure S14), and expression level of the Bcl-2 protein measured with western blot (Figure S15) (<a class="ext-link" href="/doi/suppl/10.1021/acsami.0c09494/suppl_file/am0c09494_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.

Dna-Hybrid-Gated Multifunctional Mesoporous Silica Nanocarriers for Dual-Targeted and Microrna-Responsive Controlled Drug Delivery**

Cell‐Penetrating Poly(disulfide) Assisted Intracellular Delivery of Mesoporous Silica Nanoparticles for Inhibition of Mir‐21 Function and Detection of Subsequent Therapeutic Effects

Polymeric Nanostructure Compiled with Multifunctional Components to Exert Tumor-Targeted Delivery of Antiangiogenic Gene for Tumor Growth Suppression

Near Infrared-Guided Smart Nanocarriers for MicroRNA-Controlled Release of Doxorubicin/siRNA with Intracellular ATP As Fuel.

Nanocarriers with Multi-Locked DNA Valves Targeting Intracellular Tumor-Related Mrnas for Controlled Drug Release

A Drug-Self-gated and Tumor Microenvironment-Responsive Mesoporous Silica Vehicle: "Four-in-one" Versatile Nanomedicine for Targeted Multidrug-Resistant Cancer Therapy

A Targeted DNAzyme-Nanocomposite Probe Equipped with Built-in Zn2+ Arsenal for Combined Treatment of Gene Regulation and Drug Delivery

Endogenous MicroRNA-Triggered and Real-Time Monitored Drug Release Via Cascaded Energy Transfer Payloads

Inhibition of Multidrug Resistance of Cancer Cells by Co‐Delivery of DNA Nanostructures and Drugs Using Porous Silicon Nanoparticles@Giant Liposomes

Hierarchical Nanocarriers for Precisely Regulating the Therapeutic Process via Dual-Mode Controlled Drug Release in Target Tumor Cells

Integration of simultaneous and cascade release of two drugs into smart single nanovehicles based on DNA-gated mesoporous silica nanoparticles

Dual MicroRNA-Triggered Drug Release System for Combined Chemotherapy and Gene Therapy with Logic Operation

Multiple-Responsive Mesoporous Silica Nanoparticles for Highly Accurate Drugs Delivery to Tumor Cells

A Smart Nanoassembly for Multistage Targeted Drug Delivery and Magnetic Resonance Imaging

Fluorescent Carbon Dot-Gated Multifunctional Mesoporous Silica Nanocarriers for Redox/enzyme Dual-Responsive Targeted and Controlled Drug Delivery and Real-Time Bioimaging.

A Vitamin-Responsive Mesoporous Nanocarrier with DNA Aptamer-Mediated Cell Targeting.

Hyaluronidase-Responsive Mesoporous Silica Nanoparticles with Dual-Imaging and Dual-Target Function

In Situ Amplification of Intracellular Microrna with Mnazyme Nanodevices for Multiplexed Imaging, Logic Operation, and Controlled Drug Release

The Intracellular Controlled Release from Bioresponsive Mesoporous Silica with Folate As Both Targeting and Capping Agent

An intelligent responsive macrophage cell membrane-camouflaged mesoporous silicon nanorod drug delivery system for precise targeted therapy of tumors

Precision Guided Missile-Like DNA Nanostructure Containing Warhead and Guidance Control for Aptamer-Based Targeted Drug Delivery into Cancer Cells in Vitro and in Vivo.